Journal article · 2023 · Open access

Off-label use of atypical antipsychotics- Where are we?

Rui Pedro Henriques Vaz, J. Martins, A Costa, J. Brás, R. Sousa, E. Almeida, J. Abreu, N. Castro, R. Andrade, Nuno Carlos dos Santos Pessoa Gil

European Psychiatry, 66(S1), S305 · Published 1 March 2023 · DOI 10.1192/j.eurpsy.2023.681

Open PDFView at the publisherCite this paper

In brief

“Off-label use of atypical antipsychotics- Where are we?” is a 2023 journal article by Rui Pedro Henriques Vaz and 9 co-authors, published in European Psychiatry. OpenAlex counts 5 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at European Psychiatry.

Citations
5
Most cited in
2026 (3)
Authors
10

Abstract

Introduction Nowadays, In the exercise of psychiatric clinical activity, the prescription of atypical antipsychotics is a widespread practice. However, despite the approval in the treatment of psychoses and bipolar affective disorder, where its effectiveness is clearly demonstrated, these drugs are off-label prescribed in most of the clinical situations. Objectives This work aims to clarify which atypical antipsychotics are most frequent prescribed and the clinical conditions where their off-label prescription is more common. Methods Bibliographic research in the Pubmed® database using the terms “atypical antipsychotics and off-label use” Results According to the scientific literature consulted, the off-label prescription of atypical antipsychotics may represent about 70% of the total prescription of these psychotropic drugs. Risperidone, olanzapine, quetiapine and aripiprazole are the most off-label prescribed among the atypical antipsychotics. The psychiatric conditions where atypical antipsychotics are most often off-label prescribed are addictive disorders, anxiety disorders, post-traumatic stress disorder, personality disorders, eating disorders, insomnia and dementia, where therapeutic benefits are demonstrated when carefully selected. Conclusions The off-label prescription can be interpreted from two points of view. On the one hand, it can guide innovation in clinical practice and improve symptoms in patients who do not respond to standard treatments. On the other hand, it may be associated with negative consequences due to the lack of data on safety and efficacy in these situations. Despite widespread prescribing of atypical antipsychotics, there is no evidence-based recommendation beyond psychoses and bipolar affective disorder. Thus, when prescribed, we must proceed with careful monitoring and consider the risks and benefits in relation to off-label prescription. Disclosure of Interest None Declared

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Vaz, R. P. H., Martins, J., Costa, A., Brás, J., Sousa, R., Almeida, E., Abreu, J., Castro, N., Andrade, R., & Gil, N. C. D. S. P. (2023). Off-label use of atypical antipsychotics- Where are we? European Psychiatry, 66(S1), S305. https://doi.org/10.1192/j.eurpsy.2023.681

MLA 9

Vaz, Rui Pedro Henriques, et al. “Off-label use of atypical antipsychotics- Where are we?” European Psychiatry, vol. 66, no. S1, 2023, p. S305. https://doi.org/10.1192/j.eurpsy.2023.681.

Chicago

Vaz, Rui Pedro Henriques, J. Martins, A Costa, J. Brás, R. Sousa, E. Almeida, J. Abreu, N. Castro, R. Andrade, and Nuno Carlos dos Santos Pessoa Gil. 2023. “Off-label use of atypical antipsychotics- Where are we?” European Psychiatry 66 (S1): S305. https://doi.org/10.1192/j.eurpsy.2023.681.

Harvard

Vaz, R. P. H. et al. (2023) ‘Off-label use of atypical antipsychotics- Where are we?’, European Psychiatry, 66(S1), p. S305. doi:10.1192/j.eurpsy.2023.681.

IEEE

R. P. H. Vaz et al., “Off-label use of atypical antipsychotics- Where are we?,” European Psychiatry, vol. 66, no. S1, p. S305, 2023, doi: 10.1192/j.eurpsy.2023.681.

BibTeX

@article{vaz2023label,
  title     = {{Off-label use of atypical antipsychotics- Where are we?}},
  author    = {Vaz, Rui Pedro Henriques and Martins, J. and Costa, A and Brás, J. and Sousa, R. and Almeida, E. and Abreu, J. and Castro, N. and Andrade, R. and Gil, Nuno Carlos dos Santos Pessoa},
  journal   = {European Psychiatry},
  year      = {2023},
  volume    = {66},
  number    = {S1},
  pages     = {S305},
  doi       = {10.1192/j.eurpsy.2023.681},
  url       = {https://doi.org/10.1192/j.eurpsy.2023.681}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • atypical antipsychotics
  • off-label drug use
  • risperidone
  • olanzapine
  • quetiapine
  • aripiprazole
  • addiction
  • anxiety disorders

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Vaz, R. P. H., Martins, J., Costa, A., Brás, J., Sousa, R., Almeida, E., Abreu, J., Castro, N., Andrade, R., & Gil, N. C. D. S. P. (2023). Off-label use of atypical antipsychotics- Where are we? European Psychiatry, 66(S1), S305. https://doi.org/10.1192/j.eurpsy.2023.681

How many times has this paper been cited?

5 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

Rui Pedro Henriques Vaz, J. Martins, A Costa, J. Brás, R. Sousa, E. Almeida, J. Abreu, N. Castro, R. Andrade, Nuno Carlos dos Santos Pessoa Gil.

What is the DOI of this paper?

10.1192/j.eurpsy.2023.681, permanently at https://doi.org/10.1192/j.eurpsy.2023.681. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.